LFA-1 - Specific therapy prolongs allograft survival in rhesus macaques

Journal of Clinical Investigation

Volumn 120, Issue 12, 2010, Pages 4520-4531

  Badell, Idelberto R ^a   Russell, Maria C ^a   Thompson, Peter W ^a   Turner, Alexandra P ^a   Weaver, Tim A ^a   Robertson, Jennifer M ^a   Avila, Jose G ^a   Cano, Jose A ^a   Johnson, Brandi E ^a   Song, Mingqing ^a   Leopardi, Frank V ^a   Swygert, Sarah ^a   Strobert, Elizabeth A ^b   Ford, Mandy L ^a   Kirk, Allan D ^a   Larsen, Christian P ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BELATACEPT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TS 1 22; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GRAFT SURVIVAL; IN VITRO STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACACA MULATTA; T-LYMPHOCYTE SUBSETS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649835002     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43895     Document Type: Article

References (46)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;169(950):1042-1049.
2. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975;53(1):27-42.
3. Mescher MF, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81-92.
4. Valujskikh A, Li XC. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol. 2007;18(8):2252-2261. (Pubitemid 47203840)
5. Adams AB, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest. 2003;111(12):1887-1895.
6. Ford ML, Kirk AD, Larsen CP. Donor-reactive T-cell stimulation history and precursor frequency: barriers to tolerance induction. Transplantation. 2009;87(9 suppl):S69-S74.
7. Weaver TA, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009;15(7):746-749.
8. Davignon D, Martz E, Reynolds T, Kurzinger K, Springer TA. Lymphocyte function-associated antigen 1 (LFA-1): a surface antigen distinct from Lyt- 2,3 that participates in T lymphocyte-mediated killing. Proc Natl Acad Sci U S A. 1981;78(7):4535-4539.
9. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6(1):27-36.
10. Scholer A, Hugues S, Boissonnas A, Fetler L, Amigorena S. Intercellular adhesion molecule-1- dependent stable interactions between T cells and dendritic cells determine CD8+ T cell memory. Immunity. 2008;28(2):258-270.
11. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev. 2009;229(1):294-306.
12. Lebwohl M, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349(21):2004-2013.
13. Vincenti F, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7(7):1770-1777.
14. Turgeon NA, et al. Experience with a novel efalizumab- based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10(9):2082-2091.
15. Berlin PJ, Bacher JD, Sharrow SO, Gonzalez C, Gress RE. Monoclonal antibodies against human T cell adhesion molecules - modulation of immune function in nonhuman primates. Transplantation. 1992;53(4):840-849.
16. Poston RS, et al. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation. 2000; 69(10):2005-2013.
17. Sanchez-Madrid F, et al. Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci U S A. 1982;79(23):7489-7493.
18. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol. 1983; 131(2):611-616.
19. Pitcher CJ, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol. 2002;168(1):29-43.
20. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev. 2006;211:236-254.
21. Krentz AJ, Wheeler DC. New-onset diabetes after transplantation: a threat to graft and patient survival. Lancet. 2005;365(9460):640-642.
22. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol. 2004;173(6):3653-3659.
23. Rutigliano JA, Johnson TR, Hollinger TN, Fischer JE, Aung S, Graham BS. Treatment with anti- LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol. 2004; 78(6):3014-3023.
24. Larsen CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
25. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant. 2006;6(5 pt 1):876-883.
26. Catchpole HR, Van Wagenen G. Physical growth of the Rhesus monkey (Macaca mulatta). Am J Phys Anthropol. 1956;14(2):245-273.
27. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity. 2003; 19(4):503-514.
28. Trambley J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest. 1999; 104(12):1715-1722.
29. Wang Y, Gao D, Lunsford KE, Frankel WL, Bumgardner GL. Targeting LFA-1 synergizes with CD40/CD40L blockade for suppression of both CD4-dependent and CD8-dependent rejection. Am J Transplant. 2003;3(10):1251-1258.
30. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000; 164(1):512-521.
31. Corbascio M, et al. CTLA4Ig combined with anti- LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol. 2002;10(1):55-61.
32. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol. 2002;169(9):4831-4839.
33. Wu Z, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004; 10(1):87-92.
34. Vugmeyster Y, et al. Efalizumab (anti-CD11a)- induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004;113(1):38-46.
35. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol. 2000;164(7):3627-3634.
36. Berney T, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation. 2003;76(12):1669-1674.
37. FDA Public Health Advisory Updated Safety Information about Raptiva (efalizumab). U.S. Food and Drug Administration Web site. http:// www.fda.gov/Drugs/DrugSafety/PublicHealth Advisories/ucm110605.htm. Updated February 19, 2009. Accessed May 29, 2010.
38. Neff RT, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008; 86(10):1474-1478.
39. Allison M. PML problems loom for Rituxan. Nat Biotechnol. 2010;28(2):105-106.
40. Vincenti F, et al. A phase III study of belatacep-tbased immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546.
41. Adams AB, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes. 2002;51(2):265-270.
42. Adams AB, et al. Development of a chimeric anti- CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005;174(1):542-550.
43. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413-420.
44. Barry PA, Alcendor DJ, Power MD, Kerr H, Luciw PA. Nucleotide sequence and molecular analysis of the rhesus cytomegalovirus immediate-early gene and the UL121-117 open reading frames. Virology. 1996;215(1):61-72. (Pubitemid 26038902)
45. Shi L, Ho J, Norling LA, Roy M, Xu Y. A real time quantitative PCR-based method for the detection and quantification of simian virus 40. Biologicals. 1999;27(3):241-252. (Pubitemid 30077325)
46. Rao P, Jiang H, Wang F. Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein- Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections. J Clin Microbiol. 2000;38(9):3219-3225.